GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surfa… Read more
GT Biopharma Inc (GTBP) - Total Assets
Latest total assets as of September 2025: $4.32 Million USD
Based on the latest financial reports, GT Biopharma Inc (GTBP) holds total assets worth $4.32 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GT Biopharma Inc - Total Assets Trend (1983–2024)
This chart illustrates how GT Biopharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
GT Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
GT Biopharma Inc's total assets of $4.32 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1983–2024)
This chart illustrates how GT Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GT Biopharma Inc's current assets represent 100.0% of total assets in 2024, an increase from 88.6% in 1983.
- Cash Position: Cash and equivalents constituted 93.4% of total assets in 2024, up from 57.1% in 1983.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1983.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
GT Biopharma Inc Competitors by Total Assets
Key competitors of GT Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
GT Biopharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - GT Biopharma Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - GT Biopharma Inc is currently not profitable relative to its asset base.
GT Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.70 | 1.45 | 0.16 |
| Quick Ratio | 2.70 | 1.45 | 0.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.24 Million | $ 2.10 Million | $ -29.43K |
GT Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between GT Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.18 |
| Latest Market Cap to Assets Ratio | 1.06 |
| Asset Growth Rate (YoY) | -70.0% |
| Total Assets | $4.23 Million |
| Market Capitalization | $4.47 Million USD |
Valuation Analysis
Above Book Valuation: The market values GT Biopharma Inc's assets above their book value (1.06 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: GT Biopharma Inc's assets decreased by 70.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GT Biopharma Inc (1983–2024)
The table below shows the annual total assets of GT Biopharma Inc from 1983 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.23 Million | -70.00% |
| 2023-12-31 | $14.11 Million | -15.70% |
| 2022-12-31 | $16.74 Million | -47.97% |
| 2021-12-31 | $32.17 Million | +468.26% |
| 2020-12-31 | $5.66 Million | +1329.55% |
| 2019-12-31 | $396.00K | -98.44% |
| 2018-12-31 | $25.40 Million | -90.01% |
| 2017-12-31 | $254.37 Million | +1017372.00% |
| 2016-12-31 | $25.00K | -53.70% |
| 2015-12-31 | $54.00K | -93.92% |
| 2014-12-31 | $888.00K | +504.08% |
| 2013-12-31 | $147.00K | -34.96% |
| 2012-12-31 | $226.00K | +75.19% |
| 2011-12-31 | $129.00K | -30.27% |
| 2010-12-31 | $185.00K | -86.63% |
| 2009-12-31 | $1.38 Million | +134.58% |
| 2008-12-31 | $590.00K | -87.85% |
| 2007-12-31 | $4.86 Million | -39.26% |
| 2006-12-31 | $8.00 Million | +2.45% |
| 2005-12-31 | $7.81 Million | -7.90% |
| 2004-12-31 | $8.48 Million | +331.79% |
| 2003-12-31 | $1.96 Million | -1.11% |
| 2002-12-31 | $1.99 Million | +15.34% |
| 2001-12-31 | $1.72 Million | -69.40% |
| 2000-12-31 | $5.62 Million | +8.51% |
| 1999-12-31 | $5.18 Million | -53.71% |
| 1998-12-31 | $11.20 Million | -11.11% |
| 1997-12-31 | $12.60 Million | +57.50% |
| 1996-12-31 | $8.00 Million | -19.19% |
| 1995-12-31 | $9.90 Million | -11.61% |
| 1994-12-31 | $11.20 Million | +261.29% |
| 1993-12-31 | $3.10 Million | -36.73% |
| 1992-12-31 | $4.90 Million | +2.08% |
| 1991-12-31 | $4.80 Million | -4.00% |
| 1990-12-31 | $5.00 Million | +13.64% |
| 1989-12-31 | $4.40 Million | +25.71% |
| 1988-12-31 | $3.50 Million | +6.06% |
| 1987-12-31 | $3.30 Million | 0.00% |
| 1986-12-31 | $3.30 Million | +3.13% |
| 1985-12-31 | $3.20 Million | -15.79% |
| 1984-12-31 | $3.80 Million | +8.57% |
| 1983-12-31 | $3.50 Million | -- |